Clinical-stage biotechnology company Biophytis SA (Euronext Growth Paris:ALBPS) (OTC:BPTSY) announced on Wednesday the successful transfer of BIO101 (20-hydroxyecdysone) production to industrial scale by its partner Seqens.
This first GMP-compliant batch of BIO101 (20-hydroxyecdysone), a potential treatment for respiratory decline in Duchenne Muscular Dystrophy (DMD) patients, is now available for Biophytis' clinical programme.
DMD is a severe, progressive muscle wasting disease primarily affecting boys. BIO101 (20-hydroxyecdysone) has the potential to improve respiratory function and quality of life in non-ambulatory DMD patients.
Biophytis, with orphan drug designation for DMD in Europe and the United States, is seeking partners and funding to launch a Phase 1-2 clinical trial to assess pharmacokinetics, safety and efficacy of BIO101 (20-hydroxyecdysone) in this patient population.
AstraZeneca secures EU approval for Imfinzi in limited-stage small cell lung cancer
iOncologi acquires TargImmune Therapeutics
Akeso's Penpulimab receives Chinese regulatory approval
Argent BioPharma announces positive CimetrA Phase IIb clinical trial results
ANI Pharmaceuticals secures FDA approval for ILUVIEN label expansion
Korro Bio receives FDA orphan drug designation for KRRO-110
BRAVO study confirms blue light cystoscopy reduces bladder cancer recurrence risk
Merck reports positive Phase 3 Data on HIV treatment DOR/ISL
Cantargia enrolls first patient in leukemia study with nadunolimab
Shilpa Medicare's Nor Ursodeoxycholic Acid Tablets IND receives regulatory approval in India
Centivax partners with Emery Pharma on universal flu vaccine
OsteoCentric Technologies partners with Globus Medical to expand innovative implant technology
Arvinas and Pfizer report positive Phase 3 results for vepdegestrant in breast cancer trial
PHI advances Next-Generation HoloMonitor CellSync for cell and gene therapy